Please assess the completion status of the following clinical trial:

Trial Title: Study of Adalimumab in Patients With Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with inadequate response to \>/= 1 non-steroidal anti-inflammatory drugs (NSAIDs)~* Chronic back pain with onset \< 45 years of age~* Magnetic resonance imaging (MRI) indicating active sacroiliitis or positive human leukocyte antigen-B27 (HLA-B27) blood test in addition to meeting spondyloarthritis clinical criteria~* Negative purified protein derivative (PPD) test and chest x-ray performed at Baseline visit must be negative~* Ability to administer subcutaneous injections~* General good health otherwise~Exclusion Criteria:~* Prior anti-tumor necrosis factor (TNF) therapy~* Psoriasis or psoriatic arthritis~* Fulfillment of modified New York criteria for ankylosing spondylitis~* Recent infection requiring treatment~* Significant medical events or conditions that may put patients at risk for participation~* Females who are pregnant or breast-feeding or considering becoming pregnant during the study~* History of cancer, except successfully treated skin cancer~* Recent history of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Open-label Adalimumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).